Skip to main content
Caplight Logo









TIBEAY Biosciences

TIBEAY Biosciences

Private
NijmegenHealthcare & Life Scienceshttps://tibeay-biosciences.com/

Last Round

VC Round

Apr 15, 2026

Momentum

Top 25%

of companies Caplight tracks

Company Overview

TIBEAY Biosciences is a biotechnology company that develops therapies for acute neurological conditions, such as its lead substance Ronopterin, which is designed to reduce secondary brain damage in patients with severe traumatic brain injury.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

traumatic brain injuryTBIclinical-stage biotechneurotherapeuticssecondary brain injuryiNOS inhibitorfirst-in-class therapysmall molecule drugneuroprotectiondrug developmentCNS drug developmentacute neurological diseasePhase 3 trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TIBEAY Biosciences Comparables

Compare TIBEAY Biosciences with similar companies based on industry and business-model similarity.

TIBEAY Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Astrocyte Pharmaceuticals Inc.
84%
Gryphon Bio
81%
Nyrada Inc
78%

TIBEAY Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 15, 2026

TIBEAY Biosciences Investors

Notable investors and investment history

TIBEAY Biosciences investors
InvestorRounds
MIG AGVC Round
Athos KGVC Round
MeneldorVC Round
East Netherlands Development Agency (Oost NL)VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    $41M round led by Athos KG

TIBEAY Biosciences Filings

Explore SEC and related filing metadata, where available.

TIBEAY Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TIBEAY Biosciences's valuation, stock price, and market status.

Is TIBEAY Biosciences a public or private company?

TIBEAY Biosciences is a private company.

What is the current stock price of TIBEAY Biosciences?

TIBEAY Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is TIBEAY Biosciences worth (valuation)?

Valuation information for TIBEAY Biosciences is not publicly available.

Can I buy TIBEAY Biosciences stock?

TIBEAY Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TIBEAY Biosciences's last funding round?

TIBEAY Biosciences's most recent funding round was VC Round on April 15, 2026.

Who are the main investors in TIBEAY Biosciences?

Key investors in TIBEAY Biosciences include Athos KG.

Will TIBEAY Biosciences IPO soon?

No public IPO plans have been announced for TIBEAY Biosciences.

How can I track TIBEAY Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TIBEAY Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNijmegen
Employee Range7
Year FoundedN/A
Last FundingApr 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?